Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulmonx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulmonx's regulatory disclosures and financial reporting.
Pulmonx (LUNG) announced leadership changes and compensation terms. Steven S. Williamson resigned as President, CEO, and director effective October 27, 2025. He will receive $600,000 over 12 months and COBRA reimbursement for up to 14 months, and will consult through December 1, 2025 for a $50,000 fee with continued equity vesting until that date.
The Board appointed Glendon E. French as President and CEO effective October 27, 2025, continuing as a Class I director. His offer includes a $625,000 base salary, a target bonus equal to 100% of salary, a 1,200,000-share RSU grant vesting quarterly over three years, and an 800,000-share PSU grant that vests upon time-based milestones and a performance condition of a $4.00 average closing price over 60 consecutive trading days.
Mehul Joshi resigned as CFO effective October 27, 2025 and will receive $347,625 over nine months, COBRA reimbursement up to 11 months, and a $30,000 consulting fee with equity vesting through December 1, 2025. Derrick Sung, Ph.D., was appointed COO and CFO effective November 3, 2025, with a $500,000 base salary, a 60% target bonus, a 1,200,000-share RSU, and a 400,000-share PSU with the same $4.00 performance condition.
Pulmonx Corporation is filing an S-3 shelf registration that incorporates recent SEC reports and exhibits and references its commercial and regulatory position for key products. The Zephyr Valve is commercially available in numerous countries and included in COPD treatment guidelines; the company references a pre-market approval (PMA) pathway related to a Breakthrough Device designation. The AeriSeal System holds a Breakthrough Device designation in the U.S., a Certificate of Conformity in Europe, is not FDA approved for U.S. commercial sale and is in a global clinical trial called CONVERT II to support a PMA application. The filing lists incorporated documents including Form 10-K, multiple 10-Qs, an 8-A and exhibits, and shows a reported amount of $22,040 in a table. Several exhibit and filing dates are provided, including corporate charter and bylaws references and counsel/accounting consents.
FMR LLC and Abigail P. Johnson report beneficial ownership of 2,179,993.02 shares of Pulmonx Corp common stock, representing 5.4% of the outstanding class. FMR LLC is shown with sole voting power over 2,175,878 shares and sole dispositive power over 2,179,993.02 shares; Abigail P. Johnson is reported with sole dispositive power over 2,179,993.02 shares and no voting power. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
The filing refers to an accompanying Exhibit 99 and incorporates prior powers of attorney by reference. No other person is identified as holding more than 5% of the common stock.
Pulmonx Corp. President and CEO Steven S. Williamson, who is also a director, reported selling small blocks of common stock on September 2, 2025. He sold 5,118 shares at $1.60 per share and another 4,530 shares at $1.60 per share.
According to the footnotes, both sales were made to cover tax withholding obligations tied to the vesting of restricted stock units granted in March 2024 and March 2025. After these transactions, Williamson directly beneficially owned 358,967 shares of Pulmonx common stock, which includes 2,500 shares acquired under the company’s 2020 Employee Stock Purchase Plan on August 15, 2025.
Pulmonx Corp Chief Financial Officer & PAO Mehul Joshi reported sales of 7,936 shares of common stock on September 2, 2025 at $1.60 per share. The filing explains these sales were made to cover tax withholding obligations related to RSU vesting. After these transactions, Joshi directly holds 208,489 shares of Pulmonx common stock, including 2,500 shares acquired under the 2020 Employee Stock Purchase Plan on August 15, 2025.
Pulmonx Corporation (LUNG) reporting person Geoffrey Beran, Chief Commercial Officer, disclosed multiple share dispositions on 09/02/2025. The Form 4 shows four separate sales of common stock at $1.60 per share to satisfy tax withholding tied to vested restricted stock units granted on March 1, 2022; March 1, 2023; March 1, 2024; and March 3, 2025. The reported quantities sold were 707, 1,799, 1,575, and 2,462 shares respectively, leaving beneficial ownership reported after each sale of 385,624, 383,825, 382,250, and 379,788 shares. The filing is signed by an attorney-in-fact on 09/03/2025.
David Aaron Lehman, identified as General Counsel and officer of Pulmonx Corporation (ticker LUNG), reported four separate non-derivative stock dispositions on 09/02/2025. The Form 4 shows Mr. Lehman sold 929, 3,541, 2,068 and 3,231 shares, each at $1.60 per share. Each sale is explained as occurring to cover tax withholding obligations tied to Restricted Stock Units that vested from grants dated March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025, respectively. The filing reports the reporting-person’s beneficial ownership following these transactions as 272,110, 268,569, 266,501 and 263,270 shares (direct ownership) after each reported disposition. The Form 4 is signed by Mr. Lehman on 09/03/2025.